Loading...
Market
How many patients will receive the mRNA cancer vaccine by June 30, 2025?
2
Russia•Ministry of Health•Russian•Andrey Kaprin•Radiology Medical Research Center•Russian Ministry of Health•Enteromix•Gamaleya National Research Center
Resolution / Starting Odds
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Reports from the Russian Ministry of Health or major news outlets
Story
Russia to Offer Free Personalized mRNA Cancer Vaccine in 2025, Aiming for 75-80% Tumor Reduction
Dec 17, 2024, 09:21 PM
Russia's Ministry of Health has announced the development of a cancer vaccine using mRNA technology, which is set to be distributed free of charge to Russian patients starting in early 2025. The vaccine, which will be personalized for each patient, aims to treat cancer rather than prevent it in the general population. Andrey Kaprin, General Director of the Radiology Medical Research Center of the Russian Ministry of Health, made the announcement, stating that the vaccine will cost the state 300,000 rubles per dose. The vaccine is expected to suppress tumor growth, prevent the spread of cancer, and reduce tumor size by 75-80%. Clinical trials for the oncolytic vaccine 'Enteromix' are underway, with candidates being selected for participation. The vaccine's development is part of a broader global effort, as other countries are also working on similar personalized cancer treatments, with involvement from the Gamaleya National Research Center.
View original story
Similar markets
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
No countries • 25%
1 to 5 countries • 25%
6 to 10 countries • 25%
More than 10 countries • 25%
Less than 100,000 doses • 25%
100,000 to 199,999 doses • 25%
200,000 to 299,999 doses • 25%
300,000 or more doses • 25%
Less than 10 million • 25%
10-20 million • 25%
21-30 million • 25%
More than 30 million • 25%
0-2 countries • 25%
3-5 countries • 25%
6-8 countries • 25%
9 or more countries • 25%
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%
Effective • 25%
Moderately Effective • 25%
Ineffective • 25%
Halted • 25%